Several potential new compound classes are currently undergoing different stages of clinical development. For example, rezafungin (CD101), a novel echinocandin that inhibits 1,3-β-D-glucan synthase, ...

Rezafungin acetate is under clinical development by Napp Pharmaceuticals and currently in Phase III for Aspergillosis.

With respect to echinocandin susceptibility testing, the current CLSI recommendation is to use anidulafungin as a marker of echinocandin susceptibility or resistance and to retest C glabrata isolates ...

aManchester Fungal Infection Group, Division of Evolution, Infection and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, ...

The drug candidate is a long acting echinocandin. It is administered intravaginally, subcutaneously and intravenously as a solution and a gel. The drug candidate was under development for the ...

The treatment of invasive fungal infections is complicated by both host factors and the emergence of resistance to antifungal agents. Patients with recurrent esophageal candidiasis caused by ...

Fungal biology is the scientific discipline that concerns the biology of fungi, which include unicellular microorganisms as well as large multicellular organisms. Fungal biology is sometimes ...

Background: Invasive candidiasis is increasingly prevalent in premature infants and seriously ill children, and pediatric data on available antifungal therapies are lacking. Methods: We conducted ...

Cidara Therapeutics Inc stock price live, this page displays NASDAQ CDTX stock exchange data. View the CDTX premarket stock price ahead of the market session or assess the after hours quote.